A Multicentre, Double-blind, Randomised, Parallel-group, Phase III Study to Assess Efficacy and Safety of D9421-C 9 mg Versus Mesalazine 3 g in Patients With Active Crohn's Disease (CD) in Japan
Latest Information Update: 07 Jan 2022
Price :
$35 *
At a glance
- Drugs Budesonide (Primary) ; Mesalazine
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 16 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Aug 2014 Planned End Date changed from 1 Oct 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
- 06 Aug 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.